The Latest Analyst Ratings For United Therapeutics

Throughout the last three months, 7 analysts have evaluated United Therapeutics UTHR, offering a diverse set of opinions from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Analysts have recently evaluated United Therapeutics and provided 12-month price targets. The average target is $311.14, accompanied by a high estimate of $400.00 and a low estimate of $215.00. Surpassing the previous average price target of $299.00, the current average has increased by 4.06%.

Analyzing Analyst Ratings: A Detailed Breakdown

An in-depth analysis of recent analyst actions unveils how financial experts perceive United Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to United Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of United Therapeutics compared to the broader market.
• Price Targets: Analysts provide insights into price targets, offering estimates for the future value of United Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.

To gain a panoramic view of United Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on United Therapeutics analyst ratings.

Unveiling the Story Behind United Therapeutics

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

United Therapeutics: Delving into Financials

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: United Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 25.07%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: United Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 35.32%, the company may face hurdles in effective cost management.

Return on Equity (ROE): United Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 3.71%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): United Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 3.06%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: United Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.12.

The Core of Analyst Ratings: What Every Investor Should Know

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.